Dr. Amir Horowitz's presentation showcases Purple Biotech's IM1240, a tri-specific antibody targeting cancers, demonstrating significant anti-tumor activity.
Quiver AI Summary
Dr. Amir Horowitz from Mount Sinai presented findings on Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, which engage T cells and NK cells to target cancers while addressing inhibitory signals that limit immune response. The lead antibody, IM1240, targets the 5T4 oncofetal antigen and showed significant anti-tumor effects in several treatment-resistant cancer types. Notably, it works by blocking the NKG2A immune checkpoint and activating T cells specifically in the tumor environment, which differs from traditional T-cell engagers that activate T cells earlier. Preclinical studies revealed IM1240's ability to reduce harmful cytokine release and prolonged its half-life in non-human primates, highlighting its promising safety profile and therapeutic potential. Purple Biotech aims to enhance anti-cancer efficacy while minimizing toxicity through this innovative approach, with plans to advance IM1240 toward clinical trials.
Potential Positives
- Presentation of preclinical data for IM1240 at a major symposium underscores the significance of Purple Biotech's research and enhances visibility within the oncology community.
- IM1240 has demonstrated potent anti-tumor activity in treatment-resistant cancers, suggesting its potential effectiveness in a challenging therapeutic area.
- The incorporation of a capped CD3 arm significantly improves the safety and pharmacokinetic profile of IM1240, potentially offering a broader therapeutic window compared to traditional T-cell engagers.
- The strategic approach of combining tumor-directed T-cell engagement with inhibitory signal modulation may address critical challenges in cancer immunotherapy, reinforcing the scientific foundation of the CAPTN-3 platform.
Potential Negatives
- Presentation of preclinical results rather than clinical data may raise concerns about the actual effectiveness and safety of the IM1240 candidate before it enters clinical trials.
- Heavy reliance on forward-looking statements and cautionary language in the press release suggests uncertainty regarding the company's future performance and product development outcomes.
- The emphasis on the challenges of cancer immunotherapy and the need to overcome immune resistance may indicate potential difficulties in market acceptance and regulatory approval of IM1240.
FAQ
What is Purple Biotech's CAPTN-3 platform?
CAPTN-3 is a platform of capped tri-specific antibodies designed to enhance anti-cancer immunity while minimizing toxicity.
How does IM1240 work in targeting tumors?
IM1240 targets the 5T4 antigen on various cancers and uses a unique mechanism to activate T cells only in the tumor microenvironment.
What cancer types has IM1240 shown effectiveness against?
IM1240 has demonstrated potent anti-tumor activity in lung, head and neck, and bladder cancers resistant to immunotherapy.
What advantages does the CD3 capping technology provide?
CD3 capping limits T-cell activation in circulation, enhancing safety and extending systemic exposure until reaching the tumor.
When and where was the data on IM1240 presented?
The data on IM1240 was presented during a plenary session at the ENA 2026 Symposium in Barcelona, Spain.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PPBT Hedge Fund Activity
We have seen 8 institutional investors add shares of $PPBT stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SMARTHARVEST PORTFOLIOS, LLC added 22,799 shares (+80.1%) to their portfolio in Q3 2026, for an estimated $34,654
- JANE STREET GROUP, LLC added 14,003 shares (+inf%) to their portfolio in Q3 2026, for an estimated $21,284
- CITADEL ADVISORS LLC removed 13,166 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $20,012
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 12,847 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $19,527
- INDEPENDENT ADVISOR ALLIANCE removed 11,901 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $18,089
- UBS GROUP AG added 5,721 shares (+761.8%) to their portfolio in Q3 2026, for an estimated $8,695
- HRT FINANCIAL LP added 3,589 shares (+24.5%) to their portfolio in Q3 2026, for an estimated $5,455
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PPBT Analyst Ratings
Wall Street analysts have issued reports on $PPBT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2026
To track analyst ratings and price targets for $PPBT, check out Quiver Quantitative's $PPBT forecast page.
Full Release
- Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumor immunity.
- CAPTN-3 antibodies combine an NKG2A arm that blocks an inhibitory immune checkpoint with a capped CD3 arm designed to penetrate into solid cancers and activate T cells only within the tumor microenvironment, distinguishing the platform from conventional T-cell engagers that activate T cells before reaching their target.
- IM1240, targeting 5T4, an oncofetal antigen expressed on a wide range of cancers, demonstrated potent anti-tumor activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy, including a muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab.
- NKG2A engagement is a key contributor to tumor killing, as demonstrated in studies using IM1240 and matched antibody variants in patient-derived cancer specimens, supporting the platform's strategy of targeting both innate and adaptive immune responses.
- In non-human primates, CD3 capping markedly reduced cytokine release and extended systemic exposure compared with a non-capped variant, with an approximately 8-fold longer half-life and 16-fold greater exposure, further supporting the potential of IM1240 to combine potent anti-tumor activity with a broad therapeutic window.
REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.
CAPTN-3 is Purple Biotech's platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform's lead candidate, targets 5T4.
The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.
"One of the central challenges in cancer immunotherapy is that the presence of cytotoxic immune cells within a tumor does not necessarily translate into effective tumor control. A major blind spot when introducing novel drugs is the assumption that cancer is stagnant in the face of frontline therapies," said Dr. Amir Horowitz. "Our research on the HLA-E/NKG2A pathway has shown how tumors can exploit inhibitory signals to restrain otherwise capable natural killer (NK) cells and T cells. The IM1240 findings provide compelling preclinical evidence for a therapeutic strategy that combines tumor-directed T-cell engagement with relief of NKG2A-mediated immune suppression. The activity observed in treatment-resistant human tumor models is particularly encouraging and warrants further investigation."
"These findings address two key challenges in developing T-cell engagers for solid cancers: immune resistance and systemic immune activation," said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. "Our objective is not simply to recruit more immune cells to cancers, but to enable a more effective anti-tumor response by combining targeted immune engagement with the ability to counteract inhibitory mechanisms within the tumor microenvironment. The contribution of the NKG2A arm in immunotherapy-resistant human cancers, together with the favorable safety and pharmacokinetic profile of our CD3 capping technology, strengthens the scientific foundation as we advance IM1240 toward the clinic."
Presentation Title: Conditionally activated NKG2A-engaging tri-specific antibody remodels IO-resistant human tumor microenvironments with improved tumor killing and pharmacologic safety
Abstract:
ENA26-0137
Session:
Plenary Session 7 – Proffered Papers: Novel Agents and Targets
Date and Time:
Friday, November 20, 2026, 15:24 CET
Addressing immune resistance beyond T-cell recruitment
While T-cell engagers are designed to bring cytotoxic T cells into contact with cancer cells, their activity may remain limited by immunosuppressive mechanisms within the tumor microenvironment. One such mechanism is the HLA-E/NKG2A immune checkpoint: HLA-E, expressed by tumor cells, binds the inhibitory NKG2A receptor on NK cells and subsets of cytotoxic T cells, suppressing their anti-tumor function.
Dr. Horowitz's work has helped establish the HLA-E/NKG2A pathway as an important regulator of anti-tumor immunity. Recent research from his laboratory, posted as a preprint, found that bladder cancers unresponsive to BCG immunotherapy can retain populations of potentially cytotoxic immune cells while exhibiting increased HLA-E/NKG2A inhibitory interactions. Experimental blockade of NKG2A restored immune-cell function in patient-derived tumor co-cultures, highlighting a potentially actionable mechanism of immune resistance.
These observations reinforce the scientific rationale underlying CAPTN-3: effective anti-tumor immunity may require not only bringing immune cells to cancer cells but also overcoming the inhibitory signals that prevent those immune cells from functioning effectively.
IM1240 integrates three complementary functions within a single antibody: recognition of the tumor-associated antigen 5T4, capped CD3-mediated T-cell redirection, and NKG2A engagement designed to block inhibitory signaling affecting NK cells and cytotoxic T cells. 5T4 is expressed in a variety of solid cancers and is associated with advanced disease and poor clinical outcomes.
NKG2A engagement enhances IM1240's anti-tumor activity
Data presented at ENA 2026, building on data first presented at the EACR 2026 Annual Congress in June, demonstrated that IM1240 induced anti-tumor activity in patient-derived tumor specimens collected following prior immunotherapy-containing treatment regimens: six head and neck squamous cell carcinoma metastatic lymph node samples, one muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab, and one non-small cell lung cancer (NSCLC) tumor resistant to neoadjuvant chemotherapy plus PD-1 blockade. In the dissociated head and neck and bladder specimens, tumor-cell killing required functional CD3 and NKG2A arms; in cancer cell lines, activity depended on 5T4 expression.
In a patient-derived NSCLC explant obtained following chemotherapy and PD-1 inhibitor treatment, IM1240 demonstrated substantially greater anti-tumor activity, achieving an in situ pathologic response score of 94 on a 0–100 scale, compared with 49 for an otherwise comparable antibody with an inactivated NKG2A-binding arm. Similarly, preventing CD3 activation with a non-cleavable cap reduced the response score to 38, highlighting the critical contribution of both functional components to IM1240's anti-tumor activity.
Spatial imaging of treated NSCLC explants revealed differences in immune-cell distribution and cell-cell interactions between IM1240 and the NKG2A-inactive comparator, suggesting that NKG2A engagement may influence not only direct tumor-cell killing but also the broader immune organization of the tumor microenvironment.
Collectively, these findings provide functional evidence that incorporating NKG2A targeting into a capped T-cell engager can enhance anti-tumor activity beyond CD3-mediated T-cell redirection alone.
CD3 capping supports a favorable safety and pharmacokinetic profile
In addition to its multi-arm immune mechanism, IM1240 incorporates Purple Biotech's proprietary protease-cleavable CD3 capping technology, designed to restrict full T-cell engagement until the antibody encounters proteolytic conditions associated with the tumor microenvironment.
The ENA presentation also shows that protease-mediated cap removal restores CD3 binding and immune-cell-mediated tumor killing, while a non-cleavable control remains functionally restricted.
Preclinical non-human primate studies further demonstrated that this capping strategy substantially reduced systemic cytokine responses compared with a non-capped antibody, even at higher doses, and prolonged systemic exposure through reduced clearance. As previously reported, IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg, whereas the non-capped variant, IM1222, induced robust cytokine release at just 0.03 mg/kg. IM1240 also showed an approximately 8-fold longer half-life and 16-fold greater systemic exposure.
Together, these findings support a design in which IM1240 circulates with its CD3 arm capped and is activated within the tumor microenvironment, potentially allowing sustained exposure while limiting premature peripheral T-cell activation.
About CAPTN-3
CAPTN-3 is Purple Biotech's proprietary platform of capped tri-specific antibodies designed to combine tumor-antigen recognition, T-cell engagement, and NKG2A-mediated immune checkpoint modulation. The platform integrates a protease-cleavable CD3 capping mechanism intended to limit systemic T-cell activation while enabling anti-tumor activity within the tumor microenvironment.
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity. The Company is focused on advancing CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. Capping technology is designed to confine immune activation to the tumor microenvironment and, based on preclinical data, to expand the therapeutic window compared to conventional T-cell engagers. The platform's lead candidate, IM1240, is advancing toward the clinic, and its second candidate, IM1305, is in preclinical development. The Company is headquartered in Rehovot, Israel. For additional information about the Company, please visit: https://purple-biotech.com .
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue", "potential", "designed to" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for CAPTN-3; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; our ability to raise additional capital on acceptable terms, or at all, to fund our research and development activities, including preclinical and clinical studies; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2025 as such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov .
CONTACTS:
Company Contact:
[email protected]